Clinical trials: Kidney Tumor
Diabetes Mellitus, Hypertension
The Long-term Spill-over Impact of COVID-19 on Health and Healthcare of People With Non-communicable Diseases
Objectives and aim: To evaluate the long-term spill-over (indirect) effect of Coronavirus disease (COVID-19) on health outcomes and healthcare utilization among people with non-communicable diseases and without COVID-19.
- Conditions
- Diabetes Mellitus, Hypertension, Cancer, Cardiovascular Diseases
- Trial name
- NCT05248412
- Testing
- COVID-19 outbreaks
- Where
- China
- Volunteers
- 250,000 people
- Sponsor
- The University of Hong Kong
Advanced Renal Cell Carcinoma (RCC)
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
The purpose of this study is to evaluate the safety, tolerability, and efficacy of Pumitamig alone or in combination with other agents in participants with advanced Renal Cell Carcinoma (RCC)
- Trial name
- NCT07293351
- Testing
- Pumitamig, Ipilimumab, Cabozantinib
- Where
- 95 sites in United States, Argentina and 18 more
- Volunteers
- 474 people
- Sponsor
- Bristol-Myers Squibb
Advanced Solid Tumors
Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET Protein on Tumors
This study will test a Regeneron drug called REGN13089-M404-M2980 ("study drug") to see if it can help treat previously treated, advanced solid tumors (tumors that have grown and spread to different areas of the body).
- Trial name
- NCT07863024
- Testing
- REGN13089-M404-M2980
- Volunteers
- 320 people
- Sponsor
- Regeneron Pharmaceuticals
Renal Cell Carcinoma, Ovarian Carcinoma
OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults
The study hypothesis is that a lower starting dose of anticancer tablet treatments can lead to better treatment tolerability in older patients, while the benefits of treatment can be the same.
- Conditions
- Renal Cell Carcinoma, Ovarian Carcinoma, Thyroid Carcinoma, Breast Carcinoma
- Trial name
- OPTI-DOSE (NCT05949424)
- Testing
- Olaparib, Lenvatinib, Sunitinib
- Where
- Netherlands
- Volunteers
- 30 people
- Sponsor
- University Medical Center Groningen
Renal Cell Carcinoma (RCC), Metastatic Renal Cell Carcinoma (mRCC)
PET/CT-Directed Free of Therapy for Metastatic RCC Patients With IMDC Favorable or Intermediate Risk
This phase 2 trial aims to test the feasibility and efficiency of PET/CT-directed treatment interruption strategy in metastatic renal cell carcinoma patients with IMDC favorable/intermediate risk who achieve complete (CMR) or…
- Trial name
- Perfumer (NCT07175480)
- Testing
- Intermittent PD-1/PD-L1 ICI + VEGFR-TKI
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Jinling Hospital, China
Lymphoma, Brain Neoplasms
RO4929097 in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia
Background: The anti-cancer drug RO4929097 is being tested for its ability to block blood vessel growth to tumors and slow or stop the growth of cancer cells.
- Conditions
- Lymphoma, Brain Neoplasms, Sarcoma, Osteosarcoma
- Trial name
- NCT01236586
- Testing
- RO4929097, Dexamethasone
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Plasma Cell Myeloma, Renal Failure
Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure
This phase II trial studies how well daratumumab-based therapy works in treating patients with newly diagnosed multiple myeloma with kidney failure.
- Trial name
- NCT04352205
- Testing
- Bortezomib, Daratumumab, Dexamethasone
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Emory University
Renal Cell Carcinoma
A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
The purpose of this study is to determine whether Nivolumab Combined with Cabozantinib is safe and effective compared to Sunitinib in previously untreated advanced or metastatic renal cell carcinoma
- Trial name
- CheckMate 9ER (NCT03141177)
- Testing
- Nivolumab, Cabozantinib, Sunitinib
- Where
- 135 sites in United States, Argentina and 16 more
- Volunteers
- 701 people
- Sponsor
- Bristol-Myers Squibb
Papillary Renal Cell Carcinoma
Multi-classifier System for Stratifying Stage III Papillary Renal Cell Carcinoma of Receiving Adjuvant Therapy
The goal of this trial is to test whether patients with stage III papillary renal cell carcinoma (pRCC) could benefit from adjuvant therapy or not.
- Trial name
- NCT06146777
- Testing
- Pembrolizumab
- Volunteers
- 468 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Breast Cancer, Colorectal Cancer
Marathon of Hope Cancer Centres Network Study for Ontario (MOHCCN-O)
The Marathon of Hope Cancer Centres Network (MOHCCN) is a national network of cancer centres that pursue collaborative cancer research in precision medicine (an emerging approach for disease treatment and prevention that…
- Conditions
- Breast Cancer, Colorectal Cancer, Pancreas Cancer, Kidney Cancer
- Trial name
- MOHCCN-O (NCT05403177)
- Where
- 3 sites in Canada
- Volunteers
- 500 people
- Sponsor
- University Health Network, Toronto
Renal Cancer
KIDNEY-PAGER: Analysis of Circulating Tumor DNA as a Biomarker in Renal Cancer - an Observational Trial
The overall aim of this observational study is to confirm that circulating tumor DNA (ctDNA) detected in plasma and or urine after intended curative treatment for renal cell carcinoma (RCC) can be applied in clinical practice as…
- Trial name
- KIDNEY-PAGER (NCT06145139)
- Where
- Denmark
- Volunteers
- 500 people
- Sponsor
- University of Aarhus
Melanoma, Kidney Cancer
Determining the Lymphokine Activated Killer (LAK) Cytotoxicity Present in Patients Undergoing Interleukin-2 Therapy
Therapy with Interleukin-2 stimulates lymphocytes in humans to become Lymphokine-activated Killer cells (LAK). This study will determine if these killer cells are able to kill certain standard cell-lines in the laboratory.
- Trial name
- LAK (NCT01068470)
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Loma Linda University
Kidney Cancer
Tretinoin Plus Interferon Alfa in Treating Patients With Metastatic Kidney Cancer
RATIONALE: Tretinoin may help kidney cancer cells develop into normal cells. Interferon alfa may interfere with the growth of cancer cells.
- Trial name
- NCT00003656
- Testing
- recombinant interferon alfa, tretinoin liposome
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- Weill Medical College of Cornell University
Advanced Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer
This randomized phase III trial studies gemcitabine hydrochloride, cisplatin, and bevacizumab to see how well they work compared with gemcitabine hydrochloride and cisplatin in treating patients with urinary tract cancer that has…
- Conditions
- Advanced Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Prostate Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma
- Trial name
- NCT00942331
- Testing
- Bevacizumab, Cisplatin, Gemcitabine Hydrochloride
- Where
- 873 sites in United States, Puerto Rico
- Volunteers
- 506 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Melanoma
Immunological Variables Associated to ICI Toxicity in Cancer Patients
This is a monocentric, prospective, pilot study that will enrol 435 subjects with solid tumours that are treated with immune checkpoint inhibitor(s) (ICI) alone or in combination with chemotherapy or targeted therapy.
- Conditions
- Breast Cancer, Melanoma, Non Small Cell Lung Cancer, Non-melanoma Skin Cancer
- Trial name
- NCT05429866
- Testing
- Checkpoint Blockade, Immune
- Where
- Belgium
- Volunteers
- 441 people
- Sponsor
- Jules Bordet Institute
Metastatic Renal Cell Carcinoma, Fumarate Hydratase Deficient Renal Cell Carcinoma
Talazoparib and Avelumab in Participants With Metastatic Renal Cell Carcinoma
The purpose of this study is to see whether the combination of avelumab and talazoparib can be an effective treatment for metastatic renal cell carcinoma.
- Conditions
- Metastatic Renal Cell Carcinoma, Fumarate Hydratase Deficient Renal Cell Carcinoma, Succinate Dehydrogenase Deficient Renal Cell Carcinoma
- Trial name
- NCT04068831
- Testing
- Talazoparib, Avelumab
- Where
- 7 sites in United States
- Volunteers
- 18 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Renal Tumor, Renal Malignant Tumor
Thulium Beam Coagulation Versus Suture Renorrhaphy for Hemostasis of Tumor Bed in Laparoscopic Partial Nephrectomy
To compare the outcome of thulium beam coagulation versus suture renorrhaphy for hemostasis of the tumor bed in laparoscopic partial nephrectomy.
- Trial name
- NCT06322745
- Testing
- Suture renorrhaphy only for hemostasis of the tumor bed in laparoscopic partial nephrectomy, Thulium beam coagulation and suture renorrhaphy for hemostasis of the tumor bed in laparoscopic partial nephrectomy
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Al-Azhar University
Solid Tumor (Excluding CNS), Liver Cell Carcinoma
Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells
This Phase 1, open-label, non-randomized study will enroll pediatric and young adult subjects with relapsed or refractory non-central nervous system (CNS) malignant solid tumors expressing glypican-3 (GPC3) to examine the safety…
- Conditions
- Solid Tumor (Excluding CNS), Liver Cell Carcinoma, Malignant Rhabdoid Tumor, Yolk Sac Tumor
- Trial name
- IMPACT (NCT07148050)
- Testing
- SC-CAR.GPC3xIL15.21 CAR T cells
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Seattle Children's Hospital
Adult Solid Neoplasm, Clear Cell Renal Cell Carcinoma
Sunitinib Malate in Treating Patients With Unresectable or Metastatic Kidney Cancer or Other Advanced Solid Tumors
This phase I trial is studying the side effects and best way to give sunitinib malate in treating patients with unresectable or metastatic kidney cancer or other advanced solid tumors.
- Conditions
- Adult Solid Neoplasm, Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma, Stage III Renal Cell Cancer
- Trial name
- NCT00499135
- Testing
- Computed Tomography, Fluorothymidine F-18, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)
Neuroblastoma, Rhabdomyosarcoma
Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
Hematopoietic stem cell transplantation can cure patients with blood cancer and other underlying diseases. αβ-T cell and B cell depletion has been introduced to decrease GVHD and PTLD and has demonstrated effectiveness for…
- Conditions
- Neuroblastoma, Rhabdomyosarcoma, Synovial Sarcoma, Peripheral Nerve Sheath Tumors
- Trial name
- NCT06625190
- Testing
- Miltenyi CliniMACS Prodigy ® system, Zoledronic acid
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Florida